# Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation

> **NCT02079350** · — · COMPLETED · sponsor: **Turkiye Yuksek Ihtisas Education and Research Hospital** · enrollment: 36 (actual)

## Conditions studied

- Patients Undergoing Liver Transplantation

## Interventions

- **DRUG:** %6 HES and %4 Gelofusine

## Key facts

- **NCT ID:** NCT02079350
- **Lead sponsor:** Turkiye Yuksek Ihtisas Education and Research Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-11
- **Final completion:** 2013-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079350, "Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02079350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*